No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy

被引:10
作者
Brath, Johannes M. S. [1 ]
Grill, Sonja [2 ,3 ]
Ankerst, Donna P. [2 ,3 ]
Thompson, Ian M., Jr. [4 ]
Gschwend, Juergen E. [1 ]
Herkommer, Kathleen [1 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D-81675 Munich, Germany
[2] Tech Univ Munich, Dept Life Sci, D-81675 Munich, Germany
[3] Tech Univ Munich, Dept Math, D-81675 Munich, Germany
[4] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX USA
关键词
survival rate; prostatic neoplasms; prostatectomy; age factors; family; CANCER PREVENTION TRIAL; RISK CALCULATOR; AGGRESSIVENESS; IMPACT; DATABASE; MEN;
D O I
10.1016/j.juro.2015.07.097
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Overall 1 in 5 patients with prostate cancer has a positive family history. In this report we evaluated the association between family history and long-term outcomes following radical prostatectomy. Materials and Methods: Patients treated with radical prostatectomy were identified from a German registry, and separated into positive first-degree family history vs negative family history (strictly negative, requiring at least 1 male first-degree relative older than 60 years and no prostate cancer in the family). Kaplan-Meier curves and Cox proportional hazards models were used for association analyses with biochemical recurrence-free and prostate cancer specific survival. Results: Median followup for 7,690 men included in the study was 8.4 years. Of the 754 younger patients less than 55 years old 50.9% (384) had a family history compared to 40.4% of the older patients (2,803; p < 0.001). The 10-year biochemical recurrence-free (62.5%) and prostate cancer specific survival (96.1%) rates did not differ between patients with vs without a family history, nor between the younger vs older patient groups (all p > 0.05). Prostate specific antigen, pathological stage, node stage and Gleason score were the only significant predictors for biochemical recurrence-free survival, while pathological stage, node stage (all p < 0.005) and Gleason score (Gleason 7 vs 6 or less-HR 1.711, 95% CI 1.056-2.774, p = 0.03; Gleason 8 or greater vs 6 or less-HR 4.516, 95% CI 2.776-7.347, p < 0.0001) were the only predictors for prostate cancer specific survival. Conclusions: A family history of prostate cancer has no bearing on long-term outcomes after radical prostatectomy.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 24 条
  • [1] Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer
    Ankerst, Donna P.
    Hoefler, Josef
    Bock, Sebastian
    Goodman, Phyllis J.
    Vickers, Andrew
    Hernandez, Javier
    Sokoll, Lori J.
    Sanda, Martin G.
    Wei, John T.
    Leach, Robin J.
    Thompson, Ian M.
    [J]. UROLOGY, 2014, 83 (06) : 1362 - 1367
  • [2] Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases
    Azzouzi, AR
    Valeri, A
    Cormier, L
    Fournier, G
    Mangin, P
    Cussenot, O
    [J]. UROLOGY, 2003, 61 (06) : 1193 - 1197
  • [3] Biological aggressiveness of hereditary prostate cancer: Long-term evaluation following radical prostatectomy
    Bova, GS
    Partin, AW
    Isaacs, SD
    Carter, BS
    Beaty, TL
    Isaacs, WB
    Walsh, PC
    [J]. JOURNAL OF UROLOGY, 1998, 160 (03) : 660 - 663
  • [4] Age at Diagnosis and Age at Death in Familial Prostate Cancer
    Brandt, Andreas
    Bermejo, Justo Lorenzo
    Sundquist, Jan
    Hemminki, Kari
    [J]. ONCOLOGIST, 2009, 14 (12) : 1209 - 1217
  • [5] Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK
    Brindle, Lucy A.
    Oliver, Steven E.
    Dedman, Daniel
    Donovan, Jenny L.
    Neal, David E.
    Hamdy, Freddie C.
    Lane, Janet A.
    Peters, Tim J.
    [J]. BJU INTERNATIONAL, 2006, 98 (04) : 777 - 782
  • [6] Early Detection of Prostate Cancer: AUA Guideline
    Carter, H. Ballentine
    Albertsen, Peter C.
    Barry, Michael J.
    Etzioni, Ruth
    Freedland, Stephen J.
    Greene, Kirsten Lynn
    Holmberg, Lars
    Kantoff, Philip
    Konety, Badrinath R.
    Murad, Mohammad Hassan
    Penson, David F.
    Zietman, Anthony L.
    [J]. JOURNAL OF UROLOGY, 2013, 190 (02) : 419 - 426
  • [7] Incorporation of Detailed Family History from the Swedish Family Cancer Database into the PCPT Risk Calculator
    Grill, Sonja
    Fallah, Mahdi
    Leach, Robin J.
    Thompson, Ian M.
    Freedland, Stephen
    Hemminki, Kari
    Ankerst, Donna P.
    [J]. JOURNAL OF UROLOGY, 2015, 193 (02) : 460 - 465
  • [8] Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)
    Gritz, Ellen R.
    Arnold, Kathryn B.
    Moinpour, Carol M.
    Burton-Chase, Allison M.
    Tangen, Catherine M.
    Probstfield, Jeffrey F.
    See, William A.
    Lieber, Michael M.
    Caggiano, Vincent
    Moody-Thomas, Sarah
    Szczepanek, Connie
    Ryan, Anne
    Carlin, Susie
    Hill, Shannon
    Goodman, Phyllis J.
    Padberg, Rose Mary
    Minasian, Lori M.
    Meyskens, Frank L.
    Thompson, Ian M., Jr.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (08) : 1638 - 1648
  • [9] EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, F.
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2014, 65 (01) : 124 - 137
  • [10] How common is familial cancer?
    Hemminki, K.
    Sundquist, J.
    Bermejo, J. L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (01) : 163 - 167